Participate in the RECONNECT Study:

Help Shape the Future of
Maternal Mental Health

Postpartum depression (PPD) affects countless mothers worldwide, often leaving them feeling overwhelmed, isolated, and unsupported. The RECONNECT Study, led by Reunion NeuroScience, offers new mothers the chance to contribute to critical research and help advance the future of postpartum mental health care.

Why Maternal Mental Health Matters

PPD is more than “baby blues.” It’s a serious mental health condition that can cause persistent sadness, anxiety, and exhaustion, making it difficult for mothers to care for themselves and their babies. By addressing maternal mental health head-on, we can improve the well-being of mothers, families, and communities.

What is the RECONNECT Study?

RECONNECT is a Phase 2 clinical trial led by Reunion Neuroscience, evaluating RE-104, a next-generation, fast-acting psychedelic treatment with the potential to make a significant impact on women affected by postpartum depression (PPD). Your efforts could be instrumental in identifying women who may benefit from participating in this groundbreaking study.

Why Join the RECONNECT Study?

• Advance Critical Research
  Help researchers gather data on the safety and effectiveness of psychedelic-based treatments for PPD. Your participation could help develop faster, more effective solutions for mothers in need.
• Receive Personalized, Comprehensive Care
  As a participant, you’ll be supported and monitored by experienced healthcare professionals, ensuring your safety and well-being throughout the study.
• Shape the Future of Maternal Mental Health
  By contributing to this study, you’re helping lay the foundation for innovative treatments that could benefit mothers across the globe.

Who is Eligible to Participate?

Women who have given birth within the past 15 months may be eligible if they:

• Are between the ages of 18–45
• Are not breastfeeding (or are willing to stop entirely)
• Experienced PPD symptoms during the second or third trimester or within four weeks postpartum, such as feelings of sadness, hopelessness, guilt, excessive worrying, or loss of interest in activities once enjoyed.

How to Participate

• Learn More
  M.O.M. watch our super informative Q&A with Reunion's Sr. Director of Clinical Operations. She shares details on the study’s goals, processes, and eligibility requirements.
• Screening and Enrollment
  If you meet the criteria, you’ll go through a screening process to confirm that the study is the right fit for you. Your safety and comfort are top priorities.
• Join the Study
  Once enrolled, you’ll participate under the guidance of healthcare professionals, receiving ongoing support throughout your journey.

Will I Be Compensated for Participating?

Yes, participants will receive monetary compensation for their time and reimbursement for travel expenses. All study-related care costs will be covered in full.

Your Impact

Your participation will provide critical insights into postpartum depression and help researchers develop potentially life-changing treatments.

This study moves us closer to a future where mothers facing PPD have access to faster, more effective care.

Are There Any Risks Associated With Participating?

RE104 belongs to a class of drugs called psychedelics.  In the Phase 1 Study a favorable safety profile was observed.  The most common adverse events were nausea, asymptomatic tachycardia, restlessness, headache, and agitation​. These events were reported only on the day of dosing. 

*Disclaimer:

Moms on Mushrooms (M.O.M.) is excited to share information about the RECONNECT Study in collaboration with Reunion Neuroscience, offering mothers experiencing postpartum depression a chance to explore innovative research opportunities. Please note that M.O.M. is not involved in conducting the study, and we are not responsible for its outcomes, safety, or results. Participation in the RECONNECT Study is entirely voluntary, and all medical, psychological, and safety concerns should be addressed directly with the study coordinators or your healthcare provider. Always consult a qualified medical professional before making decisions regarding your mental health or participation in clinical research.

To the fullest extent permitted by federal law and the laws of the following states—Alabama, Arizona, California, Colorado, Florida, Georgia, Hawaii, Kansas, Louisiana, Maryland, Massachusetts, Michigan, New Mexico, New York, North Carolina, Ohio, Pennsylvania, Texas, Utah, Virginia, and Wisconsin—M.O.M., including its directors, officers, employees, and agents, expressly disclaims any and all liability for any direct, indirect, incidental, consequential, or punitive damages (or any other loss or liability) arising out of or in connection with your reliance on the information provided or your participation in the study. By accessing this information, you acknowledge that you are participating at your own risk and agree to hold M.O.M. harmless from any and all claims related to the study.